2026-02-25T06:33:48-08:00 2025-12-31 271661785 CMRosen LLC 17440 Dallas Pkwy Ste 218 Dallas TX 75287 990 2025-01-01 820864340 Cure RTD Foundation CURE 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 2026-02-24 true Chad M Rosen CPA P01071321 9728181400 2025 2025-03-06 01:10:19Z Chad Griffith PO Box 1228 Red Oak TX 75154 559449 false X curertd.org X 2017 TX To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). 5 4 1 10 0 366614 529286 0 21548 30163 0 388162 559449 131712 232800 0 16540 16148 0 5501 6053 6160 154305 255108 233857 304341 1331383 1635724 0 1331383 1635724 To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). false false 233404 232800 Cure RTD Foundation is proud to have funded the five following research projects in advancement of the understanding and treatment of RTD:(a) $107,000 to Fondazione Bambino Gesu Ente Filantropico, a children's research hospital in Rome, Italy. The research project is titled "Unveiling the Underpinning of Mitochondrial Bioenergetics in RTD Motoneurons and Evaluation of Nerve Growth Factor Treatment as Therapeutic Treatment.(b) $52,000 to Children's Medical Research Institute in Australia. This is our second payment on a 2-year grant to begin understanding the eye defects of RTD patients by developing iPSC-derived Retinal Organoids: a 3D model to test the efficacy of the AAV Gene Therapy.(c) $50,000 to University of California, Irvine for a research project titled: "Post-translational modification (PTM) of hRFVT2 in human neuronal cells." The overall goal is to understand the molecular mechanisms regulating RF body homeostasis to design effective therapies for conditions like RTD. The working hypothesis is that hRFVT2 PTMs may be dysregulated in RTD pathologies, and the specific aim is to investigate the role and consequences of hRFVT2 post-translational modifications in the human fibroblast/neuronal system. The expected results will provide information on the neuronal RF transport process under normal conditions and how it is dysregulated in RTD, ultimately assisting in designing effective therapeutic strategies.(d) $14,350 to The Jackson Laboratory to fund a study titled "Pilot Biomarker Evaluation for Riboflavin Transport Deficiency (RTD)" with a purpose to validate histopathological and metabolomic/lipidomic as markers for RTD in B6.(e) $9,450 to UT Southwestern Medical Center for research on a SCL52A2 gene therapy project. 233404 true true false false false false false false false false false false false false false false false false false false true true false false false false false true false false false false false false false false false false false false false false false false false false false true 0 0 false 1 true false false false false false false false 0 false false false false false false false X 5 4 false false false false false false false true false false false true true true true true true false true false X X Carly Gilbert 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 8.00 0.00 X X 15000 0 0 Clayton Greene Secretary 3.00 0.00 X X 0 0 0 Clara O'Rourke Director 8.00 0.00 X 0 0 0 Keith Massey Director 30.00 0.00 X 0 0 0 Chad Griffith President 8.00 0.00 X X 0 0 0 15000 0 false false false 0 529286 529286 0 30163 30163 0 0 0 0 0 0 0 0 559449 30163 73800 73800 0 159000 159000 0 15000 450 10950 3600 0 0 0 0 1148 35 838 275 0 0 0 0 0 0 2611 10 2551 50 1548 670 878 1161 109 354 698 840 840 0 0 0 0 0 0 0 0 0 0 255108 233404 16203 5501 518191 792423 813192 843301 0 0 0 0 0 0 0 0 0 0 0 0 0 1331383 1635724 0 0 X 1331383 1635724 1331383 1635724 1331383 1635724 304341 X false false false X 337166 378086 380248 366614 529286 1991400 0 0 337166 378086 380248 366614 529286 1991400 54016 1937384 348 378 291 21548 30163 52728 0 0 2044128 1011 0.94780 0.95360 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true E Asia/Pacific 0 0 Grants to foreign recipients Medical research grant 52000 Europe 0 0 Grants to foreign recipients Medical research grant 107000 159000 159000 E Asia/Pacific Medical research 52000 Wire Trfr Europe Medical research 107000 Wire Trfr 2 false false false false false false Part I, Line 2 - Grantmakers Explanation For Monitoring Use of Funds Outside US Periodic reports, along with a detailed final report and analysis with findings, arerequired for each grant to account for how the grant funds are used. Future grantawards are contingent upon receipt of such reports to ensure that valuable resourcesare not wasted on research that is not beneficial. Part I, Line 3f - Method of Accounting The expenditures are reported using the cash basis of accounting. Part I, Line 3f - Investments and Expenditures All expenditures consist of research grants awarded to established institutions. Part II, Line 1 - Method of Accounting The expenditures are reported using the cash basis of accounting. true The Jackson Laboratory 600 Main St Bar Harbor ME 04609 010211513 501(c)(3) 14350 0 Medical research University of California 821 Health Science Rd Rm C348 Irvine CA 92697 943067788 Gov - Univ of CA 50000 0 Medical research UT Southwestern Medical Ctr 5323 Harry Hines Blvd Dallas TX 75390 756002868 Gov - Univ of TX 9450 0 Medical research 3 0 Grantmaker's Description of How Grants are Used Periodic reports, along with a detailed final report and analysis with findings, are required for each grant to account for how the grant funds are used. Future grant awards are contingent upon receipt of such reports to ensure that valuable resources are not wasted on research that is not beneficial. Form 990, Part VI, Section A, Line 8b There are no such committees. Form 990, Part VI, Section B, Line 11b A copy of this return was provided to the Organization's Directors via email for review and approval before filing. Form 990, Part VI, Section B, Line 12c Any director, principal officer, or member of a committee with governing boarddelegated powers, who has a direct or indirect financial interest, as defined below, is an interested person. In connection with any actual or possible conflict of interest, an interested person must disclose the existence of the financial interest and be given the opportunity to disclose all material facts to the directors and members of committees with governing board delegated powers considering the proposedtransaction or arrangement (and annual disclosure statements must be signed annually, and periodic reviews shall be conducted). After any discussion with the interested person, he/she shall leave the governing board or committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. Conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. In this case, the interesed person may make a presentation at the governing board or committee meeting, but after the presentation, he/she shall leave the meeting during the discussion of, and the vote on, the transaction or arrangement involving the possible conflict of interest. The chairperson of the governing board or committee shall, if appropriate, appoint a disinterested person or committee to investigate alternatives to the proposed transaction or arrangement. After exercising due diligence, the governing board or committee shall determine whether the Organization can obtain, with reasonable efforts, a more advantageous transaction or arrangement from a person or entity that would not give rise to a conflict of interest. If a more advantageous transaction or arrangement isnt reasonably possible under circumstances not producing a conflict of interest, the governing board or committee shall determine by a majority vote of the disinterested directors whether the transaction or arrangement is in the Organizations best interest, for its own benefit, and whether it is fair and reasonable. In conformity with the above determination, it shall make its decision as to whether to enter into the transaction or arrangement. Form 990, Part VI, Section B, Line 15b The Organization's top management official was an unpaid volunteer during the year, but compensation of the VP / Treasurer was determined and approved by a majority of independent Directors after considering comparability data reported by National Council of Nonprofits and GuideStar, as documented in the minutes in 2022. Form 990, Part VI, Section C, Line 19 These documents are available on the Organization's website and upon request.